Molecular Therapy Advances
Издатель: Elsevier · ISSN 3117-387X · 85 статей
- The potential of gene therapy to rescue telomeric and extratelomeric defects in X-linked dyskeratosis congenita
- Simultaneous gene engineering of T cells with multiple neoantigen-specific T cell receptors for adoptive cell transfer
- Co-delivery of lentiviral vectors and Cas9-containing virus-like particles enables rapid, scalable manufacture of gene-edited CAR T cells
- Natural killer cell cryopreservation: Influence of composition, temperature, and granules on post-thaw survival and function
- Host determinants of exo-rAAV production revealed by extended gene expression analysis in HEK293 cells
- In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing
- Ad5/52s fiber substitution alters Ad5 tropism, bioavailability, and plasma sensitivity
- Antisense oligonucleotide treatment following viral delivery of artificial SOD1-targeting miRNA shows improved efficacy in SOD1-G93A mice
- Neutralization of pathogenic PC-OxPL by AAV-delivered scFv as a therapeutic strategy for amyotrophic lateral sclerosis
- i.c.v. delivery of AAV9-synapsin-promoted caveolin-1 attenuates neuromuscular deficits and neuromuscular degeneration in hSOD1G93A mice
- GAA engineered to improve cellular uptake enhances correction in a preclinical hematopoietic stem cell gene therapy model of Pompe disease
- Engineering hematopoietic stem and progenitor cells to generate red blood cells as viral traps against HIV-1
- CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease
- Cytokine-independent activation of STAT5 promotes the persistence and function of CD4+ regulatory T cells
- RNA-TITER—An ADAR-based transcript detection assay for accelerated functional titer assessment of adeno-associated viruses
- Engineered muscle tissues with enhanced maturation enable the identification of clinically relevant rAAV products
- Development of the “EASY-HSV system” based on HSV-1 genome-maintaining 293 cells
- Safety and HBsAg reduction with a lentiviral vaccine J-51 in chronic hepatitis B: An investigator-initiated pilot trial
- AAVR disruption as a producer-cell engineering strategy for enhanced supernatant-based recovery of selected AAV serotypes
- Biomarker changes in cerebral adrenoleukodystrophy after gene therapy or allogeneic hematopoietic cell transplant
- Neurodevelopmental miR-135a-1-3p and miR-135b-3p promote long-distance axon regeneration after injury in the central visual pathway
- Single-cell vector copy number analysis of phenotypically defined long-term hematopoietic stem cells for gene therapy safety assessment
- Impact of downstream purification process and AAV serotype on protein-impurity clearance
- High-titer modular retroviral vectors enabled by an antisense cassette design preventing dsRNA formation during virus production
- Efficacy and safety of SENS-501, a dual-AAV otoferlin gene therapy, for DFNB9 congenital deafness
- Microdystrophins partially rescue deficits of Duchenne muscular dystrophy iPSC-cardiomyocytes
- Deciphering Mechanisms of Feeder Cell-Induced NK Cell Activation to Inform Development of Feeder-Free Expansion Systems
- Safe and efficacious gene therapy for sialidosis: From monocistronic to bidirectional AAV vectors encoding Neu1 and Ctsa
- Combination in vivo HSPC gene therapy for HIV by CCR5 knockout and decoy receptor
- Reproductive safety and germline transmission risk of onasemnogene abeparvovec following i.v. or i.c.v. administration in mice